Taysha Gene Therapies, Inc. (TSHA)

$1.54

-0.22 (-12.50%)
Rating:
Recommendation:
-
Symbol TSHA
Price $1.54
Beta 1.296
Volume Avg. 0.83M
Market Cap 96.161M
Shares () -
52 Week Range 1.35-8.93
1y Target Est -
DCF Unlevered TSHA DCF ->
DCF Levered TSHA LDCF ->
ROE -338.37% Strong Sell
ROA -144.15% Strong Sell
Operating Margin -
Debt / Equity 901.87% Strong Buy
P/E -
P/B 5.67 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TSHA news


Mr. R. A. Session II
Healthcare
Biotechnology
NASDAQ Global Select

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.